Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PROCEPT BioRobotics ( (PRCT) ) has shared an update.
On March 5, 2026, PROCEPT BioRobotics expanded its board of directors from eight to nine members and appointed former Shockwave Medical Chief Financial Officer Daniel Puckett as a Class III director, with his term running until the 2027 annual meeting of stockholders. The board also named him to its Audit Committee, enhancing the company’s financial oversight with a seasoned medtech finance executive.
The board determined that Puckett meets SEC and Nasdaq independence standards, reinforcing governance practices and qualifying him for Audit Committee service. His extensive background in senior finance roles at multiple life sciences and technology companies is expected to strengthen PROCEPT BioRobotics’ strategic and financial capabilities as it competes in the medical device and surgical robotics market.
The most recent analyst rating on (PRCT) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on PROCEPT BioRobotics stock, see the PRCT Stock Forecast page.
Spark’s Take on PRCT Stock
According to Spark, TipRanks’ AI Analyst, PRCT is a Neutral.
Overall score is held back primarily by persistent losses and ongoing cash burn despite rapid revenue growth and improving gross margins, alongside bearish technical trends (price below key moving averages and negative MACD). The latest earnings call is a relative positive due to clear 2026 growth targets and a stated timeline to EBITDA positivity, but near-term margin/OpEx headwinds and execution risk keep the score in the middle range.
To see Spark’s full report on PRCT stock, click here.
More about PROCEPT BioRobotics
PROCEPT BioRobotics operates in the medical technology industry, focusing on robotic and image-guided surgical solutions for urologic conditions. The company targets hospitals and urology practices seeking minimally invasive, technology-driven treatments, positioning itself within the growing market for precision surgical robotics and specialized medical devices.
Average Trading Volume: 1,503,941
Technical Sentiment Signal: Sell
Current Market Cap: $1.43B
For detailed information about PRCT stock, go to TipRanks’ Stock Analysis page.